

ISHL

13

**COLOGNE
GERMANY**



**OCTOBER
26-28, 2024**

**FINAL
PROGRAM**



GHSG

Saturday (26.10.2024)

08:00

08:30-11:00 Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Chairs: S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi)
Separate registration required

08:30-11:00 EHA-LYG / GHSG Joint Educational "Emerging Therapeutic Concepts in B-cell Lymphomas" (Chairs: I. Aurer, B. von Tresckow)

- Molecular and microenvironmental vulnerabilities of B-cell lymphomas (S. Leppä)
- Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma? (M. Kersten)
- Who needs bispecific antibodies as first-line treatment in aggressive lymphoma? (C. Thieblemont)
- How to implement novel ADCs in the first-line treatment of lymphoma (P. Zinzani)
- Perspectives of small molecule based first-line therapy of LBCL (T. Vassilakopoulos)
- Treatment and Trial Landscape for Malignant Lymphoma in China (Y. Song)

10:00

11:00-11:30 Break

11:30-13:00 Limited Stages
(Chairs: M. André, L. Specht)

12:00

- Intro: Treatment concepts in early-stage HL (M. André)
- Viewpoint: Systemic therapy only in the future? (R. Advani)
- Viewpoint: CMT (is it there to stay?) (J. Yahalom)

13:00-11:15 Break

13:15-14:45 The evolving role of BTKis in the treatment of B-cell Lymphomas by BelGene Switzerland GmbH, (Chair: C. Buske)

14:00

- Welcome and Introduction (C. Buske)
- BTKis in indolent lymphomas (FL, MZL) (C. Thieblemont)
- BTKis in WM (C. Buske)
- BTKis in MCL (D. Lewiss)
- Future developments (CDAC, BCL2, anti PD1/PDL1) (A. Frustaci)
- Panel discussion, audience Q&A (All)
- Closure and farewell (C. Buske)

14:45-15:15 Break

15:15-17:00 Opening and Award Ceremony
Keynote Lecture: L. Partridge

16:00

17:00-17:15 Break

17:15-20:00
Poster Session with Welcome Reception

18:00

Sunday (27.10.2024)

08:00-09:30 Pediatric and Adolescent Treatment Concepts (Chairs: J. Friedberg, C. Mauz-Körholz)

- Recent achievements and future goals in Pediatric and Young Adult HL
 - COG Perspective (S. Castellino)
 - EuroNET-PHL Perspective (C. Mauz-Körholz)
- Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization (J. Flertage)

09:30-10:00 Break

10:00-11:30 Biology & Microenvironment
(Chairs: S. Leppä, M. Shipp)

- Pathogenesis of HL (R. Küppers)
- Multimodal characterization of cHL (C. Steidl)

11:30-12:00 Break

12:00-13:30 New concepts for the treatment of B-cell lymphomas by MSD Sharp & Dohme GmbH
(Chair: P. Borchmann)

- B-cell lymphoma pathology - Illustrated for non-pathologists (W. Klapper)
- Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade (P. Borchmann)
- Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapy (S. Dietrich)

13:30-14:00 Break

14:00-15:30 Older Patients
(Chairs: P. Bröckelmann, A. Evens)

- Implementing Frailty Assessment for Treatment Guidance in HL (S. Rutherford)
- Optimal Use of Targeted Agents to Address Unmet Need in Older HL (G. Collins)

15:30-16:00 Break

16:00-17:30 Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma
by Takeda Pharmaceuticals USA, Inc. (Chair: J. Radford)

- Spotlight on ECHELON-1: 7-year survival data (J. Radford)
- Real-world insights: frontline treatment of stages III & IV cHL (C. Rusconi)
- Q&A (All faculty)
- cHL in the real-world: a case study approach (C. Mahuad, J. Radford)

17:30-18:00 Break

18:00-19:30 Advanced Stages
(Chairs: A. Herrera, J. Zijlstra)

- Individualized treatment de-escalation improves overall outcomes (P. Borchmann)
- Immune-chemotherapy overcomes the need for individualization (J. Friedberg)

Monday (28.10.2024)

08:00-09:00 Special Situations & Cases
(Chairs: A. Fosså, A. Sureda)

- Treatment Approaches in Resource Constraint Settings (Speaker: D. Balocchi, Discussant: C. Asirwa)
- HL Richter Transformation (S. Hartmann, M. Hertzberg, O. Al-Sawaf)

09:00-09:15 Break

09:15-10:15 NLPHL (Chairs: R. Hoppe, W. Klapper)

- NLPHL: HL, NHL or something else? (S. Hartmann)
- First-line treatment of NLPHL with HL-directed approaches (D. Eichenauer)
- Treatment of NLPHL with NHL-directed approaches (G. Collins)

10:15-10:30 Break

10:30-12:00 Living Beyond Lymphoma
(Chairs: F. van Leeuwen, J. Radford)

- Late consequences of drugs used in the modern era of treatment for HL (S. Ansell)
- Starting Living beyond Lymphoma with HL diagnosis (K. Behringer, M. Büttner)
- Participation in and [cost-]effectiveness of the Dutch HL survivorship care program (A. Nijdam, B. Aleman)

12:00-12:30 Break

12:30-14:00 Relapsed / Refractory HL
(Chairs: P. Armand, C. Moskowitz)

- Updated approach to second-line treatment (A. Moskowitz)
- Emerging strategies to overcome anti-PD1 resistance (S. Ansell)
- Implementing radiotherapeutic concepts in rHL care (C. Baues)

14:00-15:00 Closing Session

- WS Report (S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi)
- Best of ISHL13 (R. Advani)
- Farewell (P. Borchmann)



FINAL PROGRAM

Gürzenich Conference Center • Cologne

Scientific Sessions and Main Program

Workshop

Educational

Scientific Symposia

INTERNATIONAL SCIENTIFIC COMMITTEE

R. Advani, M. André, S. Ansell, P. Armand, C. Asirwa, O. Baiocchi,
S. Barrington, C. Baues, G. Collins, V. Diehl, H. T. Eich, A. Evens,
A. Fosså, J. Friedberg, S. Hartmann, A. Herrera, M. Hertzberg,
R. Hoppe, W. Klapper, C. Kobe, R. Küppers, S. Leppä, C. Mauz-Körholz,
A. Moskowitz, C. H. Moskowitz, W. Plattel, J. Radford, A. Rosenwald,
M. Shipp, Y. Song, L. Specht, C. Steidl, A. Sureda, F. van Leeuwen,
J. Yahalom, J. Zijlstra, P. L. Zinzani

IMPRINT

Scientific Organisation

Peter Borchmann, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, PhD, Symposium Co-Chair
Paul J. Bröckelmann, MD, Symposium Co-Chair
Dennis A. Eichenauer, MD, Symposium Co-Chair

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D-50924 Cologne

Phone: +49 (0) 221.478-5933
Fax: +49 (0) 221.478-3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conducting Organisation

KARO - KML Academic Research Organisation GmbH
Gleueler Str. 176-178, D-50935 Köln
Phone +49 221 560 779-43
Fax: +49 221 560 779-44
CEO: Dr. Birgit Fath, Michael Fuchs

Conference Management & Industrial Exhibition Secretariat

Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D-40883 Ratingen
Phone: +49 (0) 2102.669 36
Fax: +49 (0) 2102.9648 29
Email: info@tca-hanke.de

Design: Atelier Henri Winter, www.henri-winter.de

Printed by: Linsen Druckcenter GmbH

Photos by courtesy of: **Ralf Juergens** P. 5 | **Julia Vogel** P. 18, 19, 24,
26, 39 | **Thorsten Kern** P. 12, 13 | **Köln Kongress** P. 14
unsplash.com P. 15, 16/17, 22/23



ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS

DFG Deutsche
Forschungsgemeinschaft

Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program "International Scientific Events".

KARL MUSSHOFF STIFTUNG

The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" as well as the "Poster Awards".

B. BRAUN-STIFTUNG

DER GESUNDHEIT NEUE WEGE BEREITEN

Financial support was kindly provided by the B. Braun-Stiftung within their program "Scientific Events".

ACADEMIC PARTNERS



SPONSORS

We thank the following pharmaceutical companies for supporting ISHL:

PLATIN



Takeda Pharmaceuticals USA, Inc. | www.takeda.com

GOLD



BeiGene Switzerland GmbH
www.beigene.com/en-eu



MSD Sharp & Dohme GmbH
www.msd.de

BRONZE

AstraZeneca GmbH
www.astrazeneca.de

Astellas Pharma GmbH
www.astellas.com

Bristol-Myers Squibb
www.bms.com

Incyte Biosciences Germany GmbH
incyte.com

Janssen-Cilag GmbH
www.janssen-cilag.de

Lilly Deutschland GmbH
www.lilly-pharma.de

EXHIBITION HALL


The scientific exhibition takes place at the Gürzenich Conference Center in the "Isabellensaal" on the first floor.

Opening hours of the Exhibition

Saturday, October 26, 2024 11:00-18:00

Sunday, October 27, 2024 08:00-18:00

Monday, October 28, 2024 08:00-16:00



1. Takeda Pharmaceuticals USA, Inc.
2. Incyte Biosciences Germany GmbH
3. AstraZeneca GmbH
4. Janssen-Cilag GmbH
5. Lilly Deutschland GmbH
6. Astellas Pharma GmbH
7. MSD Sharp & Dohme GmbH

TABLE OF CONTENTS

WELCOME	11
GENERAL INFORMATION	12-15
SCIENTIFIC PROGRAM	
<i>Saturday, 26.10.2024</i>	
Workshop Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma	16
EHA-LYG / GHSG Joint Educational Emerging Therapeutic Concepts in B-Cell-Lymphomas	16
Scientific Session 1 Limited Stages	17
Scientific Symposium (BeiGene) The evolving role of BTKis in the treatment of B-cell Lymphomas	18
Opening Ceremony	18
Poster Session and Welcome Reception	18
<i>Sunday, 27.10.2024</i>	
Scientific Session 2 Pediatric and Adolescent Treatment Concepts	19
Scientific Session 3 Biology & Microenvironment	20
Scientific Symposium (MSD) New concepts for the treatment of B-cell lymphomas	20
Scientific Session 4 Older Patients	21
Scientific Symposium (Takeda)	21
Scientific Session 5 Advanced Stages	22
<i>Monday, 28.10.2024</i>	
Scientific Session 6 Special Situations & Cases	23
Scientific Session 7 NLPHL	23
Scientific Session 8 Living beyond Lymphoma	24
Scientific Session 9 Relapsed / Refractory HL	25
Closing Session	25

SPONSORING	26
ORAL AND POSTER PRESENTATIONS	
Advanced Stages	27
Biology and Microenvironment	32
Limited stages	37
Living beyond Lymphoma	40
Older Patients	42
Pediatric and adolescent	44
Relapsed and refractory	48
SPEAKERS AND CHAIRS	56
AWARD WINNERS	58


WELCOME

Dear Colleagues and Friends,

We warmly welcome you to our 13th International Symposium on Hodgkin Lymphoma (ISHL13), hosted by the German Hodgkin Study Group (GHSg). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL13 will cover the most recent results and emerging topics basic research, diagnostics and treatment of Hodgkin Lymphoma. In addition to the presentation of more than 100 abstracts in talks and posters, there will be invited talks, discussions, a workshop and an educational session on new therapeutic approaches in B-cell lymphoma organized jointly with the EHA-LyG. The recipients of the Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" will be honoured during the opening ceremony. On top of that, five Poster Awards have been awarded, based on the evaluation of their abstracts by an international committee.

We thank all our contributors and cordially welcome you to ISHL13!



Peter Borchmann
Symposium Chairman



Sven Borchmann
Symposium Co-Chair



Paul J. Bröckelmann
Symposium Co-Chair



Dennis A. Eichenauer
Symposium Co-Chair



General Information

Conference Office

Gürzenich Cologne | Martinstraße 29-37 | 50667 Cologne

During the conference, you can contact the Office at

Phone: +49 (0) 173 . 939 07 30

Email: info@tca-hanke.de

Opening Hours of the Conference Office

Saturday, October 26, 2024 07:00-18:00

Sunday, October 27, 2024 07:00-19:30

Monday, October 28, 2024 07:00-16:00

Accommodation

For accomodation support, please contact the conference management:

Phone: +49 (0) 2102 . 669 36

Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference. If you lose your badge, is charged a replacement fee.

Catering

During the breaks, complimentary coffee, fruit and refreshments will be available.



Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Continuing Medical Education

The 13th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 17.5 EBAH credit points.

Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room

A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.



Registration

Pre-registration will close on *October 25, 2024*. All registrations received on or after *October 26* will be considered as on-site registrations and will be charged the on-site fee.

Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on *Saturday (October 26)* and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia.

No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Microsoft PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.



Transportation

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km).

From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes.

Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at "Gürzenichstraße". The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground "Heumarkt" (about 3 minutes walking distance from the Gürzenich).

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join the poster session which is accompanied by a Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.

PROGRAM

Saturday, 26.10.2024



Workshop (Separate registration required) 08:30-11:00

Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma **ROOM: MARSILIUSSAAL**

Sally Barrington (London UK), Sven Borchmann (Cologne, DE),
Carsten Kobe (Cologne, DE), Wouter Plattel (Groningen, NL),
Davide Rossi (Bellinzona, CH)



EHA-LYG/GHSG Joint Educational 08:30-11:00

Emerging Therapeutic Concepts in B-Cell-Lymphomas

ROOM: GROSSER SAAL

Igor Aurer (Zagreb, HR), Bastian von Tresckow (Essen, DE)

08:30-08:42

Introduction

08:42-09:55

Molecular and microenvironmental vulnerabilities of B-cell lymphomas

Sirpa Leppä (Helsinki, FI)

09:55-10:08

Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

Marie José Kersten (Amsterdam, NL)

10:08-10:21

Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

Catherine Thieblemont (Paris, FR)

10:21-10:34

How to implement novel ADCs in the first-line treatment of lymphoma

Pier Luigi Zinzani (Bologna, IT)

10:34-10:47

Perspectives of small molecule based first-line therapy of LBCL

Theodoros P. Vassilakopoulos (Athen, GR)

10:47-11:00

Treatment and Trial Landscape for Malignant Lymphoma in China

Yuqin Song (Peking, CN)

Scientific Session 1

11:30-13:00

Limited Stages **ROOM: GROSSER SAAL**

Marc André (Yvoir, BE), Lena Specht (Copenhagen, DK)

11:30-11:50 Intro

Treatment concepts in early-stage HL

Marc André (Yvoir, BE)

11:50-12:10 Viewpoint

Systemic therapy only in the future?

Ranjana Advani (Stanford, US)

12:10-12:30 Viewpoint

CMT (is it there to stay?)

Joachim Yahalom (New York, US)

Q 12:30-12:40 | T049

Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

Zauchka J M, Picardi M, Filonenko K, Gotti M, Nunez J, Rossi A, Domingo-Domènech E, Giza A, Sorasio R, Visentin A, Bastos M, Paszkiewicz-Kozik E, Garcia-Sanz R, Patti C, Chauvie S, Bergesio F, Guerra L, Sureda A, Gallamini A

Q 12:40-12:50 | T050

Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries - characteristics, treatment and survival

Abalo K D, Bamdeg-Hvolbek K, Ekeblad F, Kalashnikov I, Linderoth J, Lund Hansen D, Enblad G, Jeristrom U, Goldkuhl C, Reunamo T, Pollari M, Hutchings M, Kamper P, Dahl-Sørensen R B, Lagerlöf I, Johansson A, Hansson L, Molin D, Leppä S M, El-Galaly T C, Glimelius I

Q 12:50-13:00 | T051

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

Plattel W J, Teesink S, Visser L, Voltin C, Kaul H, Schlösser H A, Kroesen B, Kobe C, Borchmann P, Diepstra A, Bröckelmann P J

Scientific Symposium (BeiGene Switzerland GmbH)

13:15-14:45

The evolving role of BTKis in the treatment of B-cell lymphomas

Christian Buske (Ulm, DE) ROOM: GROSSER SAAL

13:15-13:20 Welcome and Introduction	Christian Buske (Ulm, DE)
13:20-13:38 BTKis in indolent lymphomas (FL, MZL) (followed by Q&A)	Catherine Thieblemont (Paris, FR)
13:38-13:56 BTKis in WM (followed by Q&A)	Christian Buske (Ulm, DE)
13:56-14:14 BTKis in MCL (followed by Q&A)	David Lewis (Plymouth, UK)
14:14-14:32 Future developments (CDAC, BCL2i) (followed by Q&A)	Anna Maria Frustaci (Milan, IT)
14:32-14:44 Panel discussion, audience Q&A	All
14:44-14:45 Closure and farewell	Christian Buske (Ulm, DE)

OPENING CEREMONY

15:15-15:30 Welcome Address	Peter Borchmann (Cologne, DE), Volker Diehl (Berlin, DE)
15:30-16:00 Award Ceremony Karl-Musshoff Awards & Poster Awards, <i>Peter Borchmann, Sven Borchmann, Paul Bröckelmann, Dennis Eichenauer</i>	
16:00-17:00 Keynote Lecture	Linda Partridge (Cologne, DE)

Followed by Welcome Reception during the Poster Session



Poster Session GÜRZENICH, FOYER 17:15-20:00

All poster presenters are required to be present at their poster boards from **17:15 to 19:00**

Please join the poster presentation and take the chance to discuss the results with your colleagues.



Sunday, 27.10.2024

Scientific Session 2

08:00-09:30

Pediatric and Adolescent Treatment Concepts

ROOM: GROSSER SAAL

Jonathan Friedberg (Rochester, US), Christine Mauz-Körholz (Gießen, DE)

08:00-08:40

Recent achievements and future goals in Pediatric and Young Adult HL
1. COG Perspective (*Sharon Castellino, Atlanta, US*)
2. EuroNET-PHL Perspective (*Christine Mauz-Körholz, Gießen, DE*)

08:40-09:00

Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization (*Jamie Flerlage, Memphis, US*)

Q 09:00-09:10 | T086

EFFICACY and TOLERABILITY in DECPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY
Körholz D, Mascarin M, Landman-Parker J, Leblanc T, Kurch L, Georgi T W, Kluge R, Stoevesandt D, Pelz T, Vordermark D, Dieckmann K, Daw S, Fernandez-Teijeiro A, Avrahami G, Super L, Beishuizen A, Balwierz W, Klekawka T, Uyttebroeck A, Attarbaschi A, Cepelova M, Ceppi F, Fosså A, Prestidge T, Englund A, Hjalgrim L L, Klapper W, Hasenclever D, Mauz-Körholz C

Q 09:10-09:20 | T087

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
Castellino S M, Li H, Herrera A F, Punnett A, Le M, Parsons S K, Keller F G, Drachtman R, Lambie A, Forlenza C J, Doan A, Rutherford S, Evens A, Hodgson D, Little R F, Smith M, Dillon H, Song J, Smith S, Friedberg J W, Kelly K M

Q 09:20-09:30 | T088

Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)
Giulino-Roth L, Melgar Toledo M, Keller F G, Hoppe B S, Forlenza C J, Castellino S M, Andion Catalan M, Krystal J, Lambie A, Luisi F, Molina Morales F, Rao A V, Cooper S, Gonzalez-Llano O, Juarez Villegas L, Mauz-Körholz C, Shen J, Pillai P, Yusuf R, Kelly K M

Biology & Microenvironment ROOM: GROSSER SAAL

Sirpa Leppä (Helsinki, FI), Margaret Shipp (Boston, US)

10:00-10:25

Pathogenesis of HL

Ralf Küppers (Essen, DE)

10:25-10:50

Multimodal characterization of cHL

Christian Steidl
(Vancouver, CA)Q **10:50-11:00** | T025

Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin Lymphoma
Karihtala K, Leivonen S, Pellinen T, Karjalainen-Lindsberg M, Aoki T, Steidl C, Leppä S M

Q **11:00-11:10** | T026

Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma
Heger J, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, Bröckelmann P J, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum J K, Ullrich R T, Freilhammer M, Awerkwil S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuninger A, Borchmann P, Von Tresckow B, Borchmann S

Q **11:10-11:20** | T027

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma
Subramanian A, Su S, Flerlage J E, Alig S K, Younes S, Marks L, Pinnix C, Vega F, Steiner R E, Kumar P, Mociakova H, Sykorova A, Prochazka V, Milito C, Allen P B, Paulino D, Ramsay A, Flerlage T, Palese M, West R, Zhu C, Schroers-Martin J, Noordenbos T, Park N, Kalbasi A, Moding E, Newman A, Advani R H, Hoppe R, Diehn M, Natkunam Y, Alizadeh A A, Binkley M

Q **11:20-11:30** | T028

Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma.
Aoki T, Duns G, Rai S, Lytle A, Yin Y, Jiang A, Alig S K, Esfahani M S, Sarkozy C, Hung S, Milne K, Telenius A, Kishida M, Li M, Brien L O, Strong C, Goodyear T, Rangel J P, Hong M, Wu S, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng A P, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Nelson B H, Farinha P, Alizadeh A A, Savage K J, Scott D W, Steidl C

Scientific Symposium

12:00-13:30

(MSD Sharp & Dohme GmbH)

New concepts for the treatment of B-cell lymphomas

ROOM: GROSSER SAAL Peter Borchmann (Cologne, DE)

12:00-12:30

B-cell lymphoma pathology - illustrated for non-pathologists

Wolfram Klapper (Kiel, DE)

12:30-13:00

Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

Peter Borchmann
(Cologne, DE)**13:00-13:30**

Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

Sascha Dietrich
(Düsseldorf, DE)**Older Patients** ROOM: GROSSER SAAL

Paul Bröckelmann (Cologne, DE), Andrew Evens (New Brunswick, US)

14:00-14:25

Implementing Frailty Assessment for Treatment Guidance in HL

Sarah Rutherford
(New York, US)**14:25-14:50**

Optimal Use of Targeted Agents to Address Unmet Need in Older HL

Graham Collins (Oxford, UK)

Q **14:50-15:00** | T074

A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent
Lia K, Rask K J, R, Wold B, Fluge Ø, Fagerli U, Bersvendsen H, B Bø I, Bhargava S, Fosså A

Q **15:00-15:10** | T075

Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023
Barrett A, Wang Z, Challenger A, Darby S, Broggio J, Cutter D

Q **15:10-15:20** | T076

Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial
Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Kell F, Ko Y, Hiltz F, Kreisli S, Fuchs M, Eichenauer D A, Von Tresckow B, Borchmann P, Bröckelmann P J

Q **15:20-15:30** | T077

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826
Rutherford S, Li H, Herrera A F, Leblanc M, Ahmed S, Davison K, Casulo C, Bartlett N L, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S M, Kahl B S, Leonard J, Smith S, Friedberg J W, Evens A

Scientific Symposium

16:00-17:30

(Takeda Pharmaceuticals USA, Inc.)

Real world impact: bridging between clinical trial and real-world experience in stages III & IV 1L Hodgkin Lymphoma

ROOM: GROSSER SAAL

John Radford (Manchester, UK)

16:00-16:05 Welcome and Introduction

John Radford (Manchester, UK)

16:05-16:15 Spotlight on ECHELON-1: 7-year survival data. John Radford (Manchester, UK)

- Provide an overview of the ECHELON-1 study
- Review the latest long-term survival data up to 7 years from the ECHELON-1 study
- Evaluate the clinical implications of the ECHELON-1 study results and their implications for the use of ADCETRIS® in patients with Stage III/IV cHL

16:15-16:45 Real-world insights: frontline treatment of stages III & IV cHL.

Chiara Rusconi (Milan, IT)

- Emphasize the importance of real-world evidence to complement clinical trial data
- Analyze real-world data on the use of ADCETRIS® as a standard-of-care in previously untreated patients with Stage III/IV cHL

16:45-17:00 Q&A

All faculty

17:00-17:25 cHL in the real-world: a case study approach. Carolina Mahuad (Buenos Aires, AR), John Radford (Manchester, UK)

- Highlight the current burden of disease and unmet needs in patients with cHL
- Share real-world clinical insights on the diagnosis and general management of patients with cHL

17:25-17:30 Meeting close

John Radford (Manchester, UK)



Scientific Session 5

18:00-19:30

Advanced Stages **ROOM: GROSSER SAAL**

Alex Herrera (Duarte, US), Joséé Zijlstra (Amsterdam, NL)

18:00-18:25

Individualized treatment de-escalation improves overall outcomes Peter Borchmann
(Cologne, DE)

18:25-18:50

Immune-chemotherapy overcomes the need for individualization Jonathan Friedberg
(Rochester, US)

Q 18:50-19:00 | T001

2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
Herrera A F, Leblanc M, Castellino S M, Li H, Rutherford S, Evens A, Davison K, Punnett A, Parsons S K, Ahmed S, Casulo C, Bartlett N L, Tuscano J, Mei M, Hess B, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C H, Kaur S, Goyal G, Forlenza C, Doan A, Lambie A, Kumar P, Chowdury S, Brinker B, Sharma N, Singh A, Blum K, Perry A, Kovach A, Hodgson D, Constine L, Kostakoglu L, Prica A, Dillon H, Little R F, Shipp M A, Crump M, Kahl B S, Leonard J, Smith S, Kelly K M, Friedberg J W

Q 19:00-19:10 | T002

Development and application of a validated MRD assay in Hodgkin Lymphoma
Mattlener J, Schneider J, Schleifenbaum J K, Freihammer M, Käsgen O, Becker K, Mrd Consortium H L, Ferdinandus J, Kaul H, Schneider G, Borchmann P, Heger J, Borchmann S

Q 19:10-19:20 | T003

EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS
Hutchings M, Teesink S, Sureda-Balari A, Carvalho S, Vranovsky A, Noordzij W, Loft A, Aarens A I J, Stevens W, Diepstra A, Aleman B M, Woei-A-Jin S, Viguria M, Saevels K, Te Boome L, Tonino S, Meijnders P, Domingo-Domènech E, Hasselbalch Riley C, Nuyens S, Mallien C, Sents W, Buhrer E, Fortpied C, Plattel W J

Q 19:20-19:30 | T004

Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials
Ferdinandus J, Kaul H, Schneider G, Fuchs M, Eich H, Rosenbrock J, Baues C, Roth K S, Drzezga A, Van Heek L, Dietlein M, Borchmann P, Kober C



Monday, 28.10.2024

Scientific Session 6

08:00-09:00

Special Situations & Cases **ROOM: GROSSER SAAL**

Alexander Fosså (Oslo, NO), Anna Sureda (Barcelona, ES)

08:00-08:24

Treatment Approaches in Resource Constraint Settings

Speaker: Otavio Baiocchi (São Paulo, BR)
Discussant: Chite Asirwa (Eldoret, KE)

08:24-08:36

HL Richter Transformation Pathologists perspective

Sylvia Hartmann (Essen, DE)

08:36-08:48

HL Richter Transformation HL perspective

Mark Hertzberg (Sydney, AU)

08:48-09:00

HL Richter Transformation CLL perspective

Othman Al Sawaf (Cologne, DE)

Scientific Session 7

09:15-10:15

NLPHL **ROOM: GROSSER SAAL**

Richard Hoppe (Stanford, US), Wolfram Klapper (Kiel, DE)

09:15-09:35

NLPHL: Hodgkin, NHL or something else?

Sylvia Hartmann (Essen, DE)

09:35-09:55

First-line treatment of NLPHL with HL-directed approaches

Dennis Eichenauer (Cologne, DE)

09:55-10:15

Treatment of NLPHL with NHL-directed approaches

Graham Collins (Oxford, UK)

Session: Living beyond Lymphoma ROOM: GROSSER SAAL

Flora van Leeuwen (Amsterdam, NL), John Radford (Manchester, UK)

10:30-10:50

Late consequences of drugs used in the modern era of treatment for HL Stephen Ansell (Rochester, US)

10:50-11:10Starting Living beyond Lymphoma with HL diagnosis Karolin Behringer (Cologne, DE)
Maximilian Büttner, (Ditzingen, DE)**11:10-11:30**

Participation in and (cost-)effectiveness of the Dutch HL survivorship care program Annelies Nijdam, Berthe Aleman (Amsterdam, NL)

Q 11:30-11:40 | T062

A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations Oertel M, Holscher P, Hering D A, Klttel C, Fuchs M, Pepper N B, Lerch S, Haverkamp U, Borchmann P, Eich H T

Q 11:40-11:50 | T063

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials Juul S J, Rossetti S, Aleman B M, Van Leeuwen F E, Van Der Kaaij M A, Giusti F, Meijnders P, Raemaekers J M, Kluin-Nelemans H C, Spina M, Krzisch D, Bigenwald C, Stamatoullas A, André M, Platlet W J, Hutchings M, Maraldo M V

Q 11:50-12:00 | T064

Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors Salah Z, Selim M, Ali N, Abdelmassih A, Soliman M M, El Nabarawy N M, Hussein H, Albeltagi D M, Sidhom I

**Relapsed / Refractory HL** ROOM: GROSSER SAAL

Philippe Armand (Boston, US), Craig H. Moskowitz (Miami, US)

12:30-12:50Updated approach to 2nd-line treatment Alison Moskowitz (New York, US)**12:50-13:10**

Emerging strategies to overcome anti-PD1 resistance Stephen Ansell (Rochester US)

13:10-13:30

Implementing radiotherapeutic concepts in rrHL care Christian Baues (Bochum, DE)

Q 13:30-13:40 | T104

Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin's Lymphoma. Final Results of the BRESELIBET Prospective Trial. Sureda A, Céspedes J N, José Terol Casterá M, Hernández Mohedo F, Domingo-Domènech E, De La Cruz Vicente F, Moreno Velázquez M, Amutio Díaz M E, González Rodríguez A P, Córdoba R, Martínez Muñoz C, Romero Domínguez S, Bastos M, Rodríguez Izquierdo A, Briones Mejide J, Grell R, Casanova M, Rubio A, Avivi I, Del Campo García R, Gómez P, Vassilakopoulos T, Basic-Klinda S, Papageorgiou S, Noriega V, Javier Sánchez Blanco J, Sánchez B, Zeberio I, Garcia-Sanz R

Q 13:40-13:50 | T105

Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients Corrado F, Calabretta E, Di Trani M, Sollini M, Cristaldi V, Terzi Di Bergamo L, Brusca A, Piroso M C, Viscovo M, Bramanti S, Chiti A, Hohaus S, Santoro A, Rossi D, Carlo-stella C

Q 13:50-14:00 | T106

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin Moskowitz A, Shah G, Ganesan N, Hancock H, Davey T, Chang T, Munayirji B, Douglas M, Santarosa A M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Intlekofer A, Hamlin P, Horwitz S, Johnson W, Kumar A, Lue J, Luttwak E, Noy A, Owens C, Palomba M, Salles G, Steiner R E, Stuver R, Torka P, Vardhana S, Zelenetz A, Yahalom J, Dogan A, Schoder H, Moskowitz C H

Closing Session ROOM: GROSSER SAAL**14:00-14:25 Workshop Report**

Sally Barrington (London, UK), Carsten Kobe (Cologne, DE), Sven Borchmann (Cologne, DE), Wouter Platlet (Groningen, NL), Davide Rossi (Bellinzona, CH)

14:25-14:45 Best of ISHL13

Ranjana Advani (Stanford, US)

14:45 Farewell

Peter Borchmann (Cologne, DE)



We would very much like to thank all of our partners for their generous sponsoring.

Name of Sponsor	Total Sponsoring Amount	Sponsoring Benefit
Astellas Pharma GmbH	€ 5.000,00	Booth
AstraZeneca GmbH	€ 5.000,00	Booth
BeiGene Switzerland GmbH	€ 43.000,00	Symposia
Bristol Myers Squibb	€ 10.000,00	Educational
Incyte Biosciences Germany GmbH	€ 6.000,00	Booth
Janssen-Cilag GmbH	€ 5.000,00	Booth
Lilly Deutschland GmbH	€ 5.000,00	Booth
MSD Sharp & Dohme GmbH	€ 48.000,00	Symposia, Booth
Takeda Pharmaceuticals USA, Inc.	€ 67.000,00	Symposia, Booth

ABSTRACTS ORAL AND POSTER PRESENTATIONS

Posters will be presented during the Poster Session and Welcome Reception (Saturday, October 26, 17:15 to 20:00).

All poster presenters are required to be present at their poster boards from 17:15 to 19:00

Advanced Stages

Talks

Q T001

2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
Herrera A F, Leblanc M, Castellino S M, Li H, Rutherford S, Evens A, Davison K, Punnett A, Parsons S K, Ahmed S, Casulo C, Bartlett N L, Tuscano J, Mei M, Hess B, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C H, Kaur S, Goyal G, Forlenza C, Doan A, Lambie A, Kumar P, Chowdury S, Brinker B, Sharma N, Singh A, Blum K, Perry A, Kovach A, Hodgson D, Constine L, Kostakoglu L, Prica A, Dillon H, Little R F, Shipp M A, Crump M, Kahl B S, Leonard J, Smith S, Kelly K M, Friedberg J W

Q T002

Development and application of a validated MRD assay in Hodgkin Lymphoma
Borchmann P, Moccia A, Greil R, Herzberg M, Fosså A, Hüttmann A, Keil F, Dierlamm J, Schaub V, Hänel M, Novak U, Meissner J, Hellmuth J, Mathas S, Zijlstra J M, Viardot A, Hertenstein B, Martin S, Giri P, Kreissl S, Fuchs M, Schneider G, Rosenwald A, Klapper W, Eich H T, Baues C, Hallek M, Kobe C, Diehl V, Engert A

Q T003

EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

Hutchings M, Teesink S, Sureda-Balari A, Carvalho S, Vranovsky A, Noordzij W, Loft A, Aarens A I J, Stevens W, Diepstra A, Aleman B M, Woei-A-Jin S, Viguria M, Saevels K, Te Boome L, Tonino S, Meijnders P, Domingo-Domènech E, Hasselbalch Riley C, Nuyens S, Mallien C, Sents W, Buhner E, Fortpied C, Plattel W J

Q T004

Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

Ferdinandus J, Kaul H, Schneider G, Fuchs M, Eich H, Rosenbrock J, Baues C, Roth K S, Drzezga A, Van Heek L, Dietlein M, Borchmann P, Kobe C

Posters**P005**

Accuracy of Ann Arbor Stage Assignment Based on PET/CT Reports Using a Large Language Model in Hodgkin Lymphoma Patients

Voltin C, Kottlors J, Borchmann P, Gödel P, Drzezga A, Dietlein M, Dratsch T

P006

Adaptation of a PET-based treatment strategy and outcomes of patients with Advanced Hodgkins Lymphoma in resource constrained settings

Singh C, Lekshmon K S, Jain A, Khadwal A, Bal A, Srinivasan R, K Basher R, Malhotra P, Prakash G

P007

Are Four Cycles of BEACOPP Escalated Sufficient for Patients with Advanced Hodgkin Lymphoma and PET-2 Deauville Score 3?

Mocikova H, Markova J, Gaherova L, Maco M, Maule E, Michalka J, Janikova A, Sykorova A, Stepankova P, Hradska K, Duras J, Kredatusova A, Prochazka V, Kral Z, Kozak T

P008

Brentuximab Vedotin (BV) Exposure and Long-Term Efficacy Analysis in Patients With Classical Hodgkin's Lymphoma (cHL): Analysis of Phase 3 ECHELON-1 Study

Zhang Z, Zhang D, Jie F, Fenton K, Rustia E, Glenn C, Fanale M, Feldman T, Ansell S M, Chia Y

P009

Brentuximab vedotin plus chemotherapy in patients with previously untreated Stage III/IV classical Hodgkin lymphoma: seven-year overall survival analysis from ECHELON-1

Hutchings M, Ansell S M, Straus D J, Connors J M, Jurczak W, Kim W, Gallamini A, Ramchandren R, Friedberg J W, Advani R H, Evens A M, Savage K J, Eom H, Feldman T, Abramson J S, Dong C, Savani B, Zomas A, Fenton K, Radford J

P010

Clinico-pathological correlation in patients with positive end of treatment PET after pembrolizumab + AVD for untreated classic Hodgkin lymphoma

Lynch R, Naresh K, Demirci R, Chen D, Ujjani C, Poh C, Warren E H, Smith S, Shadman M, Till B, Raghunathan V M, Tseng Y, Gopal A K

P011

Data Collaborations Accelerate Pediatric Hodgkin Lymphoma Research Through NODAL

Jamie F, Birz S, Castellino S M, Henderson T O, Lucas J, Renfro L A, Zhou Y, Volchenboum S, Furner B, Watkins M, Kelly K M

P012

Exploring the capability of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index to predict the lack of an early complete metabolic response in a multicentric Italian cohort

Cellini A, Assanto G M, Romano A, Santuccio G, Vitale C, Montalbano M C, Cavarretta C A, Angotzi F, Ruocco V, Serafin A, Danesin N, Coscia M, Di Raimondo F, Del Giudice I, Piazza F, Trentin L, Visentin A

P013

High rates of undetectable MRD by PhasED-Seq on interim and end of treatment timepoints in untreated advanced stage CHL treated with pembrolizumab + AVD

Lynch R, Alig S K, Ujjani C, Poh C, Warren E H, Smith S, Shadman M, Till B, Raghunathan V M, Tseng Y, Ottemiller S, Joy B, Fessel M, Du H, Vandermeer J, Kelly A, Rasmussen H, Voutsinas J, Alizadeh A A, Gopal A K

P014

Hodgkins Lymphoma in Latin American patients: Ten years experience in a reference center in Mexico.

Hernández Company A, Santiago Jiménez G, Torres Castellanos K, Barranco Lampón G I, Zazueta Pozos J F, Pérez Sámano D d J, Martínez Moreno E, Gallardo Rodríguez A G, Martínez Murillo C

P015

Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model

Maurer M, Parsons S K, Upshaw J, Rodday A M, Friedberg J W, Gallamini A, Federico M, Hawkes E, Hodgson D, Johnson P, Mou E, Savage K, Luigi Zinzani P, Evens A

P016

Implementing BrECADD for the treatment of adult patients with newly diagnosed advanced stage classical Hodgkin's lymphoma (AS-cHL). A single center experience

Gakopoulos A, Giatra C, Panousieris M, Bristogiannis S, Apsemidou A, Mitkou A, Masaoutis C, Baltadakis I, Bouzani M

P017

INDIRECT CLINICAL TRIALS COMPARISONS OF TREATMENTS FOR ADVANCED-STAGED HODGKIN LYMPHOMA WITH INDIVIDUAL PATIENT DATA EXTRACTION.

Visentin A, Cellini A, Angotzi F, Ruocco V, Serafin A, Danesin N, Bevilacqua A, Cavarretta C A, Piazza F, Trentin L

P018

Lower doses of dacarbazine as a safer strategy in Hodgkin Lymphoma's intensive treatment protocol (modified escalated BEACODD): preliminary retrospective analysis of a single and public center in Brazil.

Gomes Oliveira Braga A, Hilario Dulley L, Garcia Rodrigues G, Costa Fortier S, Sergio Chiattonne C, Maira Bueno Da Silveira T

P019

Pembrolizumab + AVD in classic Hodgkin lymphoma: Low rates of febrile neutropenia despite frequent grade 4 neutropenia

Kuczmarski T, Ujjani C, Poh C, Warren E H, Smith S, Shadman M, Till B, Raghunathan V M, Tseng Y, Du H, Vandermeer J, Kelly A, Rasmussen H, Voutsinas J, Gopal A K, Lynch R

P020

Real-life experience with BV-AVD combination in advanced stage classical Hodgkin Lymphoma: A multicenter study from Greece

Liaskas A, Angelopoulou M, Vryttia P, Verrou E, Piperidou A, Lefaki M, Georgopoulou A, Machairas A, Stoumbos D, Kaiafa G, Sioni A, Kanellias N, Arapaki M, Constantinou E, Gogos D, Siakantari M, Katodritou E, Panayiotidis P, Papageorgiou S, Vassilakopoulos T

P021

SERUM TARC COMBINED WITH FDG-PET IMAGING IMPROVES INTERIM RESPONSE EVALUATION IN CLASSIC HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS OF GERMAN HODGKIN STUDY GROUP HD16 AND HD18 TRIALS

Plattel W J, Jablonski J, Lohmann M, Von Tresckow B, Sureda A, Pegtel M, Zijlstra J M, Radford J, Kroesen B, Visser L, Fuchs M, Borchmann P, Diepstra A, Borchmann S

P022

TREATMENT OF CLASSICAL HODGKIN'S LYMPHOMA (cHL) WITH BREN-DUXIMAB VEDOTIN - DOXORUBICIN - VINBLASTINE - DACARBAZINE (BV-AVD). ONE CENTER'S EXPERIENCE

Giatra C, Polyviou A, Kontitsi K, Tzenou T, Panousieris M, Babali V, Apsemidou A, Bristogiannis S, Gakopoulos A, Theodorou E, Kanellis G, Baltadakis I, Gigantes S, Bouzani M

P023

Trial In Progress: CTEP 10590, NORM: Nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

Steiner R E, Lee H J, Green M, Lin R, Pinnix C, Moskowitz A, Yahalom J, Chihara D

P024

Trial in Progress: PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory (R/R) Hematologic Malignancies

Kim T M, Lewis K, Alderuccio J, Lee H J, Derenzini E, Zinzani P L, Ladetto M, Phillips E H, Ghesquieres H, Lemonnier F, Morschhauser F, Sureda-Balari A, Rodriguez Izquierdo A, Borchmann P, Weinstock M, Svoboda J, Dean E, Urosevic J, Meyer S, Chen R, Yu T, Reyes R, Beyfuss K, Collins G P

Biology and Microenvironment

Talks

Q T025

Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

Karihtala K, Leivonen S, Pellinen T, Karjalainen-Lindsberg M, Aoki T, Steidl C, Leppä S M

Q T026

Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

Heger J, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, Bröckelmann P J, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum J K, Ulrich R T, Freihammer M, Awerkiew S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuning A, Borchmann P, Von Tresckow B, Borchmann S

Q T027

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

Subramanian A, Su S, Flerlage J E, Alig S K, Younes S, Marks L, Pinnix C, Vega F, Steiner R E, Kumar P, Mocikova H, Sykorova A, Prochazka V, Milito C, Allen P B, Paulino D, Ramsay A, Flerlage T, Palese M, West R, Zhu C, Schroers-Martin J, Noordenbos T, Park N, Kalbasi A, Moding E, Newman A, Advani R H, Hoppe R, Diehn M, Natkunam Y, Alizadeh A A, Binkley M

Q T028

Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

Aoki T, Duns G, Rai S, Lytle A, Yin Y, Jiang A, Alig S K, Esfahani M S, Sarkozy C, Hung S, Milne K, Telenius A, Kishida M, Li M, Brien L O, Strong C, Goodyear T, Rangel J P, Hong M, Wu S, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng A P, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Nelson B H, Farinha P, Alizadeh A A, Savage K J, Scott D W, Steidl C

Posters

P029

A novel in vitro model to study the effect of PD1 inhibition in Hodgkin Lymphoma at a molecular level

Martinez Alcala R, Lei Y, Visser L, Diepstra A, Veldman J

P030

Cell-Free DNA as Potential Prognosticator and Tracking Tool in Classic Hodgkin Lymphoma: Molecular Profiling and Clinical Correlations.

Veltmaat N, Tan G W, Zhong Y, Teesink S, Terpstra M, Bult J, Nijland M, Kluiver J, Diepstra A, Van Den Berg A, Plattel W J

P031

Characteristics and outcomes of patients with Hodgkins Lymphoma with Paraneoplastic manifestations

Singh C, K S. L, Jain A, Khadwal A, Bal A, Srinivasan R, K Basher R, Malhotra P, Prakash G

P032

CK2 FAVORS T-CELL CHEMOTAXIS THROUGH THE RELEASE OF SOLUBLE FACTORS BY HODGKIN AND REED-STERNBERG CELLS

Visentin A, Frezzato F, Capasso G, Mouawad N, Castronuovo M, Cellini A, Angotzi F, Serafin A, Cavarretta C A, Ruocco V, Bevilacqua A, Manni S, Facco M, Scarmozzino F, Pizzi M, Vianello F, Piazza F, Trentin L

P033

Final analysis of correlation between serum TARC concentration and MTV,TLG in a cohort of Classical Hodgkin Lymphoma during first line treatment.

Sordi B, Manuel C, Signori L, Abenavoli E, Lombardo A, Romano I, Palazzo M, Coltro G, Zizza M, Pancani F, Nassi L, Puccini B

P034

Gene Expression Signature Reveals a Protective Role of B-cells in the Progression of classical Hodgkin Lymphoma patients

Donati B, Lazić T, Nizzoli M E, Bavieri A, Durmo R, Valli R, Gennaro A, Ascione C, Ruffini A, Pozzi S, Versari A, Merli F, Ciarrocchi A, Luminari S

P035

Histological Grading in Nodular Sclerosis Classical Hodgkin Lymphoma Identifies a Subgroup of Patients with Higher Early Response Rates and Better Prognosis in the Contemporary Treatment Era

Cellini A, Scarmozzino F, Cavarretta C A, Angotzi F, Ruocco V, Serafin A, Danesin N, Gregorian M, Vio S, Crimi F, Vianello F, Piazza F, Pizzi M, Trentin L, Visentin A

P036

Immune landscape associated with response to brentuximab vedotin with ipilimumab and/or nivolumab in relapsed Hodgkin lymphoma in E4412 Phase 1

Diefenbach C, Gonzalez-Kozlova E, Del Valle D M, Huang H, Jegede O, Barcessat V, Tuballes K, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Moravec R, Altreuter J, Yawa Duose D, Kahl B S, Ansell S M, Yu J, Cerami E, Lindsay J, Wistuba I, Kim-Schulze S, Gnjatic S

P037

Impact of Clonal hematopoiesis of indeterminate potential in classical Hodgkin Lymphoma

Hesselager C, Hollander P, Johansson A, Linderöth J, Enblad G, Weström S, Eriksson D, Munters A R, Molin D, Baliakas P, Amini R

P038

Molecular pathogenesis of Hodgkin Lymphoma

Beeck L, Budeus B, Schneider M, Farsijani N, Bein J, Hartmann S, Hansmann M, Küppers R

P039

New understanding of oncogenic mechanisms in classical Hodgkin lymphoma

Pirosa M C, Salehi M, Brusca G, Terzi Di Bergamo L, Jauk F, Forestieri G, Bocchetta S, Piffaretti D, Moia R, Cristaldi V, Di Trani M, Galimberti G A, Pini K, Spina V, Giordano C, Condoluci A, Annunziata S, Bergesio F, Boldorini R, Borsatti E, Bulian P, Chauvie S, Cuzzocrea M, Gerber B, Kurlapski M, Larocca L M, Rinaldi A, Rodari M, Romanowicz G, Sacchetti G M, Stathis A, Stüssi G, Zangrilli I, Calabretta E, Corrado F, Pinto A, Mazzucchelli L, Gattel V, Zaucha J M, Santoro A, Hohaus S, Cavalli F, Zucca E, Gaidano G, Carlo-stella C, Tzankov A, Ceriani L, Rossi D

P040

Plasma proteins and Hodgkin's Lymphoma: Proteome-wide Mendelian randomization and colocalization analyses

Pan T, Zhang J, Wang X, Song Y

P041

Proteomic profile in classical Hodgkin Lymphoma patients with high inflammation

Collin J, Risebro R, Mattsson Ulfstedt J, Pettersson E, Hellström M, Glimelius I, Berglund M, Enblad G, Freyhult E, Molin D

P042

Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity

Andersen M D, Wolter K, Enemark M H, Lauridsen K L, Hamilton-Dutoit S J, Starklint J, D'Amore F, Ludvigsen M, Honoré B, Kamper P

P043

SPATIAL ORGANIZATION OF THE TUMOR MICROENVIRONMENT IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA AND T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: INSIGHTS FROM A PILOT COHORT STUDY

Kalashnikov I, Kalander K, Junquera A, Autio M, Leivonen S, Dunkel J, Färkkilä A, Leppä S M

P044

Sulforaphane, a Natural Compound, Inhibits Cell Growth and Promotes NK Cell-Mediated Anti-Tumor Immune Responses Through cGAS-STING Pathway in Classical Hodgkin Lymphoma

Xagoraris I, Yang Y, Bougka E, Trogrlic D, Xyderou P, Stathopoulou K, An Bihn Nordentoft C, Herold N, Lundqvist A, Rassidakis G Z

P045

T-cell diversity and exclusion of blood-derived clonally expanded T-cells in the tumor microenvironment of classical Hodgkin Lymphoma

Seifert N, Reinke S, Grund J, Müller-Meinhard B, Richter J, Heilmann T, Schlöber H, Biehl-Kotrova M, Brüggemann M, Borchmann P, Bröckelmann P J, Altenbuchinger M, Klapper W

P046

Transcriptional reprogramming by mutated IRF4 in lymphoma

Schleussner N, Cauchy P, Franke V, Giefing M, Fornes O, Vankadari N, Assi S, Costanza M, Weniger M A, Akalin A, Anagnostopoulos I, Bukur T, Casarotto M, Damm F, Daumke O, Edginton-White B, Gebhardt C, Grau M, Grunwald S, Hansmann M, Hartmann S, Huber L, Kärger E, Lusatis S, Nörenberg D, Obier N, Pannicke U, Pfaus A, Reisser A, Rosenwald A, Schwarz K, Sundararaj S, Weilemann A, Winkler W, Xu W, Lenz G, Rajewsky K, Wassermann W, Cockerill P, Scheidereit C, Siebert R, Küppers R, Grosschedl R, Janz M, Bonifer C, Mathas S

P047

Trial in Progress: Evaluating Combination of Nivolumab and Axitinib in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (NAHL)

Shah H, Hu B, Boucher K, Stephens D

P048

Tumor-associated macrophages correlate with skeletal involvement in classic Hodgkin lymphoma

Andersen M D, Wolter K, Enemark M H, Pedersen M A, Gormsen L C, Lauridsen K L, Starklint J, Hamilton-Dutoit S J, D'Amore F, Ludvigsen M, Kamper P

Limited stages**Talks****Q T049**

Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

Zaucha J M, Picardi M, Filonenko K, Gotti M, Nunez J, Rossi A, Domingo-Domènech E, Giza A, Sorasio R, Visentin A, Bastos M, Paszkiewicz-Kozik E, Garcia-Sanz R, Patti C, Chauvie S, Bergesio F, Guerra L, Sureda A, Gallamini A

Q T050

Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries - characteristics, treatment and survival

Abalo K D, Bamdeg-Hvolbek K, Ekeblad F, Kalashnikov I, Linderoth J, Lund Hansen D, Enblad G, Jerlstrom U, Goldkuhl C, Reunamo T, Pollari M, Hutchings M, Kamper P, Dahl-Sørensen R B, Lagerlöf I, Johansson A, Hansson L, Molin D, Leppä S M, El-Galaly T C, Glimelius I

Q T051

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

Plattel W J, Teesink S, Visser L, Voltin C, Kaul H, Schlösser H A, Kroesen B, Kobe C, Borchmann P, Diepstra A, Bröckelmann P J

P052

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Seelisch J, Hu B, Renfro L A, Keller F G, Duvall A, Henderson T O, Wu Y, Cho S Y, Hoppe B S, Milgrom S, Roth L G, Grover N S, Lacasce A S, Kahn J M, Yao S, Parsons S K, Khan N, Mailhot Vega R, Hinds P S, Allen P B, Evens A M, Schoder H, Castellino S M, Kelly K M

P053

Development and validation of the Early stage (ES) classic Hodgkin Lymphoma (cHL) International Prognostication Index (E-HIPI): an individualized prediction model for progression-free survival (PFS) utilizing objective and continuous variables

Rodday A M, Radford J, Maurer M, Upshaw J, Counsell N, Rossetti S, Advani R H, Andre M, Chang C, Gallamini A, Hay A, Hodgson D, Hoppe R, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J M, Savage K, Xiang Q, Parsons S K, Evens A

P054

Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial (Trial in Progress)

Bröckelmann P J, Kaul H, Fuchs M, Kobe C, Baues C, Klapper W, Von Tresckow B, Borchmann P

P055

King Faisal Specialist Hospital and Research Centre
Dada R, Apostolidis J, Belal Ibrahim R, Ahmed Salem A, Ibrahim Mahmoud M, Asif Iqbal H, Boubakra T, Ghatasheh H, Nawaz A, Halahleh K

P056

Pediatric Infradiaphragmatic Hodgkin's lymphoma: a unique identity

Hamoda A, Ezzeldeen N, Moussa E, El Wakeel M A, Khorshed E, Mehesen M, Elnashar A, Abdelkareem S, Zaghloul M

**P057**

Proton therapy for limited stage classical Hodgkin lymphoma patients (PRO-Hodgkin): an interim analysis of clinical outcome.
Goldkuhl C, Bäck A, Enblad G, Glimelius I, Hansson L, Jerlström U, Johansson A, Kahlmeter-Brandell J, Linderoth J, Palma M, Molin D

P058

Real-life data on morbidity and cause-specific mortality after combined modality treatment for classical Hodgkin lymphoma 2006-2015.

Lagerlöf I, Wikman P, Enblad G, Goldkuhl C, Palma M, Fohlin H, Glimelius I, Molin D

P059

Safe Radiotherapy for Pregnant Women with Hodgkin's Lymphoma: Myth or Reality?

Wojciechowska-Lampka E, Rosińska M, Lampka J, Osiadacz W, Tajer J, Kuchcińska A

P060

Total metabolic tumor volume impairs the successful detection of circulating tumor DNA (ctDNA) in early-stage Hodgkin lymphoma patients - the preliminary report from the RAFTING trial.

Bednarek M, Chauvie S, Piroso M, Guerra L, Versari A, Gregianin M, Bergesio F, Pini K, Galimberti G A, Bocchetta S, Salehi M, Wyszomirski A, Rambaldi A, Picardi M, Filonenko K, Kurlapski M, Sureda A, Rossi D, Gallamini A, Zaucha J M

P061

Variation in the delivery of radiotherapy as part of frontline curative treatment for Hodgkin lymphoma across healthcare providers in England

Jones D, Clarke P, Wolstenholme J, Cutter D, Broggio J

Living beyond lymphoma

Talks

Q T062

A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

Oertel M, Hölscher P, Hering D A, Kittel C, Fuchs M, Pepper N B, Lerch S, Haverkamp U, Borchmann P, Eich H T

Q T063

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Juul S J, Rossetti S, Aleman B M, Van Leeuwen F E, Van Der Kaaij M A, Glusti F, Meijnders P, Raemaekers J M, Kluin-Nelemans H C, Spina M, Krzisch D, Bigenwald C, Stamatoullas A, André M, Plattel W J, Hutchings M, Maraldo M V

Q T064

Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

Salah Z, Selim M, Ali N, Abdelmassih A, Soliman M M, El Nabarawy N M, Hussein H, Albeltagi D M, Sidhom I

Posters

P065

An exploration of patient specific and systemic delays as part of the diagnostic odyssey in patients with Hodgkin lymphoma- an analysis of the Lymphoma Coalition's 2022 Global Patient Survey

Kalloger S, Watson A, Sajkowski S, Warwick L

P066

Analysis of fetal dose exposure by modern radiation therapy in pregnant patients with supradiaphragmatic Hodgkin lymphoma - A phantom-based simulation

Oertel M, Smeets G, Vogt I, Wolters H, Kittel C, Hering D A, Greve B, Haverkamp U, Eich H T

P067

Excellent outcomes with low intensity treatment based on age and stage in children and adults with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): a 10yr retrospective analysis of patients from 8 UK centres.

Jackson T, Kirkwood A A, Ediriwickrema K, Gohil S, Zhang X, Collins G P, Hall G, Hopkins D, Mckay P, Shankar A, Fiaccadori V

P068

Hodgkin's Lymphoma in Armenia: Diagnostic Delays and the Unintended Benefits of COVID-19 Screening

Sahakyan L, Soghomonyan D, Voskanyan A, Stepanyan A, Stepanyan L, Melik-Andreasyan M, Evoyan L, Saaryan M

P069

Male sex and longer time since Hodgkin lymphoma diagnosis are associated with non-attendance at survivorship clinics

Lammers E M, Aleman B M, Schaapveld M, Zijlstra J M, Janus C P, De Weijer R J, Schippers M G, Boersma R S, Gommers S S, Kappert M, Van Leeuwen F E, Nijdam A

P070

Management and Follow-Up of Pregnancy in Patients Diagnosed with Hodgkin's Lymphoma

Ghukasyan N, Andranik P, Edita G, Lusine D, Lusine S, Melik-Andreasyan M, Khachatryan H

P071

MyHodgkin MyHealth (MHMH): Mobile App for patient-entered data to collect long term follow up (LTFU) after Hodgkin Lymphoma (HL) treatment

Wong Doo N, Falconer J, Kailainathan G, Lawrence P E, Klemm G, Chapman N, Trotman J

P072

Study of long-term survivorship of lymphoma patients - a multi-center longitudinal study of return to work and quality of life (ALLY)
Eyl-Armbruster R E, Wendler J, Böttinger R, Neumaier S, Jensch A, Knott M, Rössle S, Giesen N, Strentzsch J, Schindler V, Kopp H, Greiner J, Denzlinger C, Illerhaus G

P073

The national Breast screening After Radiotherapy Dataset (BARD) identifies women in England at very high risk (VHR) of breast cancer (BC) following radiotherapy (RT) and ensures timely referral to the correct national screening pathway
Radford J, Williams J, Payne E, Roberts K, Jenkins J, Mackle A, Macklin-Doherty A, Swerdlow A, McCabe M, Massey T, Worthington D, Yates-Bolton N, Aznar M, Cowan R, Howell S

Older Patients

Talks

Q T074

A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent
Lia K, Rask Kj R, L. Wold B, Fluge Ó, Fagerli U, Bersvendsen H, B. Bø I, Bhargava S, Fosså A

Q T075

Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023
Barrett A, Wang Z, Challenger A, Darby S, Broggio J, Cutter D

Q T076

Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial
Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko Y, Hitz F, Kreissl S, Fuchs M, Eichenauer D A, Von Tresckow B, Borchmann P, Bröckelmann P J

Q T077

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥ 60 years with advanced stage classical Hodgkin Lymphoma (cHL) enrolled on SWOG S1826
Rutherford S, Li H, Herrera A F, Leblanc M, Ahmed S, Davison K, Casulo C, Bartlett N L, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S M, Kahl B S, Leonard J, Smith S, Friedberg J W, Evens A

Poster

P078

'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma - a multicentre, retrospective study
Wilson M, Haynes E, Parsons K, Hopkins D, Robertson E, Ferguson G, Quinn D, Murray J, Osborne W, Leach M, Mckay P

P079

Anthracycline-based therapy for elderly HL patients: a retrospective series from a single South Italy center.
Tarantino V, Porrazzo M, Leone M M A, Torretta E, Mulè A, Patti C, Castagna L

P080

Brentuximab vedotin monotherapy is a feasible and effective treatment in elderly and frail patients with classical Hodgkin lymphoma: Results of the prospective GHSG-NLG phase II BVB trial.
Fosså A, Molin D, Bröckelmann P J, Schneider G, Schnetzke U, Linderoth J, Kamper P, Leppä S M, Meissner J, Schaub V, Lia K, Fuchs M, Borchmann P, Böll B

P081

Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II BVB Trial
Bröckelmann P J, Böll B, Molin D, Schneider G, Leppä S M, Meissner J, Kamper P, Hutchings M, Haaber Christensen J, Schnetzke U, Fuchs M, Eichenauer D A, Von Tresckow B, Kaul H, Borchmann P, Fossa A

P082

Elderly Classical Hodgkin Lymphoma: Croatian Cooperative Group for Hematological Diseases (KroHem) Experience

Hude Dragičević I, Ivek I, Bašić-Kinda S, Mišura Jakobac K, Ivić Čikara M, Petrić M, Periša V, Vučinić Ljubičić I, Sušac Zrna I, Krečak I, Mokwa D, Čolak T, Dreta B, Dujmović D, Aurer I

P083

Hodgkin Lymphoma in Older Patients (HoOP)- A European Retrospective Study

Barrett A, Kirkwood A A, Burton C, Clifford R, Henderson R, McKay P, Osborne W, Shah N, Collins G P

P084

Patients over the age of 60 years treated with Hodgkin's lymphoma at our Clinic

Tóthfalusi D, Pinczés L I, Dobó B, Illés A, Miltényi Z

P085

Treatment Efficacy, Overall Survival, and Disease-Free Survival in Elderly versus Younger Patients with Hodgkin's Lymphoma:

A Decade of Experience at a Latin American Reference Hospital
Santiago Jimenez G, Hernández Company A, Torres Castellanos K, Barranco Lampón G I, Zazueta Pozos J F, Pérez Sámano D d J, Martínez Moreno E, Martínez Murillo C, Gallardo A G

Pediatric and adolescent

Talks

Q T086

EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

Körholz D, Mascarín M, Landman-Parker J, Leblanc T, Kurch L, Georgi T W, Kluge R, Stoevesandt D, Pelz T, Vordermark D, Dieckmann K, Daw S, Fernandez-Teijeiro A, Avrahami G, Super L, Beishuizen A, Balwierz W, Klekawka T, Uyttebroeck A, Attarbaschi A, Cepelova M, Ceppi F, Fosså A, Prestidge T, Englund A, Hjalgrim L L, Klapper W, Hasenclever D, Mauz-Körholz C

Q T087

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
Castellino S M, Li H, Herrera A F, Punnett A, Le M, Parsons S K, Keller F G, Drachtman R, Lambie A, Forlenza C J, Doan A, Rutherford S, Evens A, Hodgson D, Little R F, Smith M, Dillon H, Song J, Smith S, Friedberg J W, Kelly K M

Q T088

Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Giulino-Roth L, Melgar Toledo M, Keller F G, Hoppe B S, Forlenza C J, Castellino S M, Andion Catalan M, Krystal J, Lambie A, Luisi F, Molina Morales F, Rao A V, Cooper S, Gonzalez-Llano O, Juarez Villegas L, Mauz-Körholz C, Shen J, Pillai P, Yusuf R, Kelly K M

Posters

P089

An audit of compliance with recommendations for screening and management of Hodgkin's lymphoma in teenager and young adult population. Results from a baseline audit within the northern health and social care trust.

Yousif E, Sweeney K, Niblock A

P090

Brentuximab-Associated Alopecia in Children and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Bender J D, Faulhaber A T, Norris R E

P091

Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of pediatric Hodgkin lymphoma

Gao H, Duan Y

P092

CNS Involvement in Pediatric Hodgkin Lymphoma: A Retrospective Analysis of AHOD1331, EuroNet-PHL-C1 and EuroNet-PHL-C2 from SEARCH for CAYAHL

Pabari R, McCarten K, Flerlage J E, Lai H, Mauz-Körholz C, Dieckmann K, Palese M, Kaste S C, Castellino S M, Kelly K M, Stoevesandt D, Kurch L

P093

Definition of independent lymph node regions in pediatric HL. An expert consensus by an International Collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL)

Stoevesandt D, Steglich J, Kurch L, Flerlage J E, Mauz-Körholz C, Körholz D, Kluge R, Vordermark D, Hoppe B S, Dieckmann K, Gowdy C, Voss S

P094

Dose-dense chemotherapy enables elimination of radiotherapy for a majority of patients with low-risk pediatric Hodgkin lymphoma: a report on HODO8 from the Pediatric Hodgkin Consortium

Flerlage J E, Feraco A, Zhou Y, Zheng Y, Jiang L, Lucas J, Friedmann A, Weinstein H, Yock T, Shulkin B, Kaste S C, Marks L, Ehrhart M, Dixon S, Howard S, De Alarcon P, Luna-Fineman S, Geddis A, Larsen E, Marcus K, Billett A, Donaldson S, Hudson M, Metzger M, Krasin M, Link M

P095

Group-Based Trajectories of Health-related Quality of Life (HRQoL) among Patients with High-Risk Pediatric Hodgkin Lymphoma treated on the Children's Oncology Group (COG) AHOD 1331 Study

Williams A, Rodday A M, Renfro L A, Wu Y, Henderson T O, Keller F G, Castellino S M, Parsons S K

P096

International Harmonization Efforts for Pediatric, Adolescent and Young Adult Hodgkin Lymphoma: A Current Report from the SEARCH FOR CAYAHL Group

Seelisch J, Kelly K M, Punnett A, Mauz-Körholz C, Marks L, Palese M, Pabari R, Dieckmann K, Lai H, Gowdy C, Steglich J, Drachtman R, Voss S D, Hoppe B S, McCarten K, Kurch L, Belshuizen A, Stoevesandt D, Flerlage J E

P097

Is the EVA regimen (etoposide, vinblastine, doxorubicin) safe and effective for treating Hodgkin's lymphoma in pregnant patients?

Wojciechowska-Lampka E, Rosińska M, Lampka J, Nowecki Z, Osiadacz W, Tajer J, Romejko-Jarosińska J

P098

Omitting radiation in young adult females with Hodgkin's disease. Is there an impact on outcome?

Hamoda A, Semary S, Naguib E, El Wakeel M A, Zaghloul M, Abdelaziz S, Hamza M, Moussa E

P099

PET/CT Response Assessment in Pediatric Hodgkin Lymphoma. Deauville Score 3 Does it really reflect Negativity?

Moussa E, Hamoda A, Semary S, Salama M, Fakhry M, Mehesen M, Elwakeelc M, Naguib E, Elnashar A, Attia A, Sedky M

P100

Prognostic Significance of PD1, PD-L1 Expression, Pathological Subtypes and Metabolic Activity on 18F-FDG PET/CT in Refractory/Relapsing Pediatric Hodgkin Lymphoma

Khedr R, Khorshed E, Hassanein O, Abdelrahman H, El Wakeel M A, Zaghloul M, Hamoda A

P101

Towards Incorporation of Pediatric Specific Criteria in the Revised Lugano Classification of Hodgkin Lymphoma (HL) Staging and Response: Report from the ICML Pediatric Subcommittee

Kelly K M, Flerlage J E, Hoppe B S, Kluge R, Mauz-Körholz C, WöBmann W

P102

Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Children's Oncology Group AHODO431

Hoppe B S, Milgrom S, Renfro L A, Wu Y, Schwartz C, Constine L, Hodgson D, McCarten K, Kelly K M, Keller F G, Castellino S M

P103

Updated Results From the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With High-Risk Classical Hodgkin Lymphoma (cHL) With Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Mauz-Körholz C, Vinti L, Daw S, Ceraulo A, Michel G, Cepelova M, Sabado Alvarez C, Fagioli F, Ducassou S, Buffardi S, Leblanc T, Hoppe B S, Keller F G, Kelly K M, Giulino-Roth L, Landman-Parker J, Shen J, Pillai P, Yusuf R, Beishuizen A

Relapsed and refractory

Talks

Q T104

Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin's Lymphoma. Final Results of the BRESELIBET Prospective Trial. *Sureda A, Céspedes J N, José Terol Casterá M, Hernández Mohedo F, Domingo-Domènech E, De La Cruz Vicente F, Moreno Velázquez M, Amutio Díaz M E, González Rodríguez A P, Córdoba R, Martínez Muñoz C, Romero Domínguez S, Bastos M, Rodríguez Izquierdo A, Briones Mejjide J, Greil R, Casanova M, Rubio A, Avivi I, Del Campo García R, Gómez P, Vassilakopoulos T, Basic-Klinda S, Papageorgiou S, Noriega V, Javier Sánchez Blanco J, Sánchez Z, Zeberio I, García-Sanz R*

Q T105

Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

Corrado F, Calabretta E, Di Trani M, Sollini M, Cristaldi V, Terzi Di Bergamo L, Bruscazzin A, Piroso M C, Viscovo M, Bramanti S, Chiti A, Hohaus S, Santoro A, Rossi D, Carlo-Stella C

Q T106

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin *Moskowitz A, Shah G, Ganesan N, Hancock H, Davey T, Chang T, Munayirji B, Douglas M, Santarosa A M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Intlekofer A, Hamlin P, Horwitz S, Johnson W, Kumar A, Lue J, Luttwak E, Noy A, Owens C, Palomba M, Salles G, Steiner R E, Stuver R, Torcka P, Vardhana S, Zelenetz A, Yahalom J, Dogan A, Schoder H, Moskowitz C H*

Posters

P107

A short course of nivolumab (N) followed by chemotherapy BGD and autologous transplantation (aHCT) as the salvage treatment for relapsed/refractory (r/r) Hodgkin Lymphoma (cHL) patients - the preliminary results of the N-BURGUND trial of PLRG

Zauchka J M, Paszkiewicz-Kozik E, Małkowski B, Taszner M, Rybka J, Chromik K, Kołkowska-Leśniak A, Subocz E, Targoński Ł, Ceklarz P, Witkowska M, Domańska-Czyż K, Giza A, Kobylecka M, Voltin C, Romejko-Jarosińska J, Ostrowska B, Świerkowska M, Druzd-Sitek A, Kurlapski M, Bednarek M, Romanowicz G, Swoboda R, Góra-Tybor J, Hałka J, Wróbel T, Giebel S, Helbig G, Lech-Marańda E

P108

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II AERN Trial

Bröckelmann P J, Bühnen I, Zijlstra J M, Mathas S, Roth K S, García-Marquez M, Sillaber C, Meissner J, Fosså A, Greil R, Trautmann-Grill K, Rosenbrock J, Plattel W J, Schlösser H A, Kobe C, Fuchs M, Borchmann P, Baues C

P109

Are refractory/relapsed Hodgkin lymphoma patients can be recognized earlier?

Dobó B, Tóthfalusi D, Pinczés L I, Miltényi Z, Illés A

P110

Autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma after PD-1 inhibitors salvage regimens is effective in third- or fourth-line therapy

Kotselyabina P, Borzenkova E, Chekalov A, Lepik K, Fedorova L, Ivanov A, Lepik E, Kondakova E, Moiseev I, Mikhailova N, Kulagin A

P111

C-MOPP chemotherapy is a highly efficacious regimen for patients with relapsed classical Hodgkin lymphoma following PD-1 inhibitor treatment failure.

Ma S, Vilcassim S, Fedele P, Grigoriadis G, Low M, Gregory G P, Opat S, Gilbertson M

P112

Coformulated Favezelimab and Pembrolizumab (pembro) Versus Chemotherapy (chemo) in Patients (Pts) With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) Refractory to Anti-PD-1 Therapy: The Phase 3 KEYFORM-008 Study

Lavie D, Timmerman J, Garcia-Sanz R, Kim W, Kim T M, Avigdor A, Dierickx D, Jagadeesh D, Molin D, Ozcan M, Gokmen Sevindik O, Saeed H, Sidi Y, Pillai P, Yusuf R, Herrera A F

P113

Dose-dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-year Long Term Follow Up

Lynch R, Cassaday R, Smith S, Cowan A, Warren E H, Shadman M, Till B, Ujjani C, Morris K, Rasmussen H, Voutsinas J, Gopal A K

P114

Early Progression of Disease Predicts Poor Survival in Patients with Classic Hodgkin Lymphoma: Czech Hodgkin Lymphoma Study Group analysis

Procházka V, Sýkorová A, Kredátusová A, Lukášová M, Štěpánková P, Papajík T

P115

Efficacy and safety of prolgolimab monotherapy or in combination with bendamustine in second-line therapy for r/r classic Hodgkin lymphoma: trial in progress (Prolgo-HL)

Fedorova L, Lepik K, Kotselyabina P, Semenova A, Shpirko V, Volchenkov S, Markelov V, Chekalov A, Zyuzgin I, Tumyan G, Mikhailova N, Kulagin A

P116

Extended Follow-up from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412)

Diefenbach C, Jegede O, Ansell S M, Steidl C, Natkunam Y, Scott D W, Mehta-Shah N, Amengual J E, Forlenza C J, Cole P, Bartlett N L, David K, Advani R H, Ambinder R F, Thomas S P, Ibrahim S, Kahl B S

P117

Frequency and indicators of primary refractoriness in low-risk non-bulky early-stage Hodgkin's lymphoma patients and negative interim PET - report from the RAFTING trial

Filonenko K, Domingo-Domènech E, Nunez J, Carpio C, Romano A, Tarella C, Rodriguez Izquierdo A, Garcia R, Trentin L, Gotti M, Kurlapski M, Bednarek M, Gallamini A, Zaucha J M

P118

Abstract withdrawn

P119

Inclusion of Brentuximab vedotin in salvage regimens before transplant benefits relapsed/refractory Hodgkin lymphoma patients in a real-world setting - a multicenter study in Portugal

Santos P, Tavares S, Costa C, Neto M, Paulos Mesquita I, Silva C, R. Pinto F, Tomé A, Gerivaz R, Monteiro A, Coutinho R, Roque A, Pinto A L, Badiol M, Ribeiro T, Dias M, Vagos Mata A, Mendes T, Miranda F, Mousinho F, Cabral R, Ramalheira S, Alpoim M, Mesquita B, Pierdomenico F, Gomes Da Silva M

P120

KEYNOTE-B68: Updated efficacy and safety of pembrolizumab every six weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL)
Mcdonald A, Verburgh E, Gotti M, Pinto A, Zaucha J M, Ivanov V, Melnichenko V, Moclíkova H, Ozcan M, Patti C, Farias J, Goncalves I, Kuchkova O, Mayer J, Saydam G, Tomassetti S, Pathiraja K, Ryland K, Yusuf R, Jurczak W

P121

Nivolumab based salvage in Relapsed/Refractory Hodgkin Lymphoma: experience from a tertiary care hospital in north India
Sanjeev S, Gala D, Saha S, Singh M K, Nazar A, Ora M, Chandra D, Rahman K, Gupta R, Kashyap R

P122

Open-label phase 1 study to evaluate the safety of SGN-35T in patients with relapsed/refractory CD30-expressing lymphoid malignancies (SGN35T-001; trial in progress)
Feldman T, Ramchandren R, Lee H J, Popradi G, Collins G P, Morillo D, Yan M, Chen T L, Kim Y H

P123

Outcome of treatment with the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab in patients with classical Hodgkin lymphoma - A retrospective analysis on consecutive patients from a well-defined region.
Mansur Z, Lundin E, Hansson L, Engelbrekt Wahlin B, Palma M

P124

Outcomes in patients with relapsed/refractory Hodgkin lymphoma after failure following frontline brentuximab vedotin-based treatment
Ong S Y, Chen L, Merryman R, Shah H, Stuver R, Lacasce A S, Falade A, Baron K, Ganesan N, Chang T, Durani U, Othman T, Armand P, Mei M, Moskowitz A J, Herrera A F

P125

Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
Dreyfuss A, Ganesan N, Alencar A, Boardman A, Caron P, Chang T, Davey T, David K, Dogan A, Epstein-Peterson Z, Falchi L, Fregonese B, Ghione P, Hamlin P, Horwitz S, Imber B, Intlekofer A, Isrow D, Joffe E, Johnson W, Kumar A, Lariviere M, Lue J, Luttwak E, Mcnicholas M, Moore Z, Munayirji B, Noy A, Owens C, Palomba L, Patel J, Plastaras J, Santarosa A M, Schöder H, Shah G, Steiner R E, Stuver R, Svoboda J, Torka P, Vardhana S, Zelenetz A, Salles G, Yahalom J, Moskowitz C H, Moskowitz A

P126

Pembrolizumab in Combination with Salvage Chemotherapy for First-Relapsed or Refractory Classical Hodgkin Lymphoma: The Multicenter Phase II Pembro-CORE Study (Trial in Progress)
Tharmaseelan H, Gillessen S, Bühnen I, Kaul H, Kobe C, Klapper W, Fuchs M, Borchmann S, Bröckelmann P J, Borchmann P, Von Tresckow B

P127

Phase II Trial Evaluating the Anti-CD47 Antibody Magrolimab in Combination with Pembrolizumab in Patients with Relapsed / Refractory Classic Hodgkin Lymphoma
Schroers-Martin J, Spinner M, Merryman R, Chang C, Yeung A, Silin C, Powell M, Armand P, Shipp M A, Advani R H

P128

Preliminary Results of the Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) with Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma (KESTREL-01, NCT04510636)
Abeyakoon C, Sheikh S, Wang L, Aoki T, Bhella S, Kridel R, Kukreti V, Prica A, Vijenthira A, Laister R, Crump M, Kuruvilla J

P129

Radiomic and biological biomarkers in relapsed/ refractory classical Hodgkin Lymphoma: an analysis from the ANIMATE study
Barrett A, Kirkwood A A, Vidal M M, Warbey V, Burton C, Barrans S, Mell T, Tooze R, Davies J R, Westhead D, Tyson C, Lawrie E, Clifton-Hadley L, Miall F, Ledieu R, Phillips E H, Osborne W, Culligan D, Shah N, Pottinger B, Cunningham D, Pettengell R, Martinez-Calle N, Johnson P, Gallop-Evans E, Peggs K, Booth S, Ardavan A, Barrington S F, Collins G P

P130

Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
Stuver R, Vardhana S, Ganesan N, Mahajan N, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Hernandez-Ilizaliturri F, Horwitz S, Intlekofer A, Johnson W, Karmali R, Kumar A, Lue J, Luttwak E, Noy A, Owens C, Palomba M, Salles G, Schoder H, Sermer D, Steiner R E, Torka P, Zelenetz A, Von Keudell G, Moskowitz A

P131

Results of allogeneic stem cell transplantation in Hodgkin lymphoma - long term experience.
Rusináková Z, Vranovský A, Ladická M, Cingel'ová S, Sopko L, Bojtárová E, Mikušková E, Drgoňa L

P132

Richter transformation of CLL to Hodgkin lymphoma
Maco M, Mocikova H, Kalinová M, Prouzová Z, Flodr P, Panovská A, Arpáš T, Šimkovič M, Kozák T

P133

Serum TARC monitoring during routine follow-up leads to early diagnosis of relapse in classic Hodgkin lymphoma
Teesink S, Visser L, Keijzer K, Kroesen B, Nijland M, Van Den Berg A, Diepstra A, Plattel W J

P134

THE BELIEVE STUDY: EFFECTIVENESS AND SAFETY FOR RE-TREATMENT WITH BRENTUXIMAB-VEDOTIN IN RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA: A RETROSPECTIVE MEDICAL CHART REVIEW IN SPAIN.
 NCT:04998331
Sureda-Balari A, Garcia-Sanz R, Domingo-Domènech E, Capote F J, Gutierrez A, Rodriguez Izquierdo A, Grande M, Baeza-Montañez L

P135

The coincidence of relapsed Hodgkin lymphoma and ovarian carcinoma as a role-model for ctDNA MRD monitoring
Hanáčková V, Grohmann J, Flodr P, Papajík T, Navrátilová J, Procházkva V

P136

The prognostic value of Δ SUVmax and TARC in the first-line treatment of classical Hodgkin lymphoma
Pinczés L I, Tóthfalusi D, Dobó B, Barna S, Farkas B, Garai I, Fejes Z, Nagy Jr. B, Illés A, Miltényi Z

P137

Updated Analysis of a Phase 1/2 Study Evaluating Pembrolizumab (pembro) Plus the Anti-Lymphocyte-Activation Gene 3 (LAG-3) Antibody Favezelimab for Anti-PD-1-Naive Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Johnson N A, Lavie D, Borchmann P, Gregory G P, Herrera A F, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceau West R, Pillai P, Yusuf R, Timmerman J

P138

Updated Analysis of a Phase 1/2 Study Evaluating Pembrolizumab (pembro) Plus the Anti-Lymphocyte-Activation Gene 3 (LAG-3) Antibody Favezelimab for Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma (cHL)
Timmerman J, Lavie D, Johnson N A, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory G P, Keane C, Tzoran I, Vucinic V, Zinzani P L, West R M, Pillai P, Yusuf R, Herrera A F

Advani, Ranjana: *radvani@stanford.edu*
Aleman, Berthe: *b.aleman@nki.nl*
Al Sawaf, Othman: *othman_al-sawaf@uk-koeln.de*
André, Marc: *marc.andre@uclouvain.be*
Ansell, Stephen: *ansell.stephen@mayo.edu*
Armand, Philippe: *Philippe_Armand@dfci.harvard.edu*
Asirwa, Chite: *chiteasirwa@gmail.com*
Aurer, Igor: *aurer@mef.hr*
Baiocchi, Otavio: *obaiocchi@gmail.com*
Barrington, Sally: *sally.barrington@kcl.ac.uk*
Baues, Christian: *christian.baues@klinikum-bochum.de*
Behringer, Karolin: *karolin.behringer@uk-koeln.de*
Borchmann, Peter: *peter.borchmann@uk-koeln.de*
Borchmann, Sven: *sven.borchmann@uk-koeln.de*
Bröckelmann, Paul: *paul.broeckelmann@uk-koeln.de*
Buske, Christian: *christian.buske@uni-ulm.de*
Büttner, Maximilian: *max.buettner99@web.de*
Castellino, Sharon: *sharon.castellino@emory.edu*
Collins, Graham: *graham.collins@ouh.nhs.uk*
Cottereau, Anne Segolene: *anne-segolene.cottereau@inserm.fr*
Diehl, Volker: *v.diehl@uni-koeln.de*
Dietrich, Sascha: *haem-onk.direktion@med.uni-duesseldorf.de*
Eichenauer, Dennis: *dennis.eichenauer@uk-koeln.de*
Evens, Andrew: *ae378@cinj.rutgers.edu*
Ferdinandus, Justin: *justin.ferdinandus@uk-koeln.de*
Flerlage, Jamie: *jamie_flerlage@urmc.rochester.edu*
Fosså, Alexander: *aff@ous-hf.no*
Friedberg, Jonathan: *jonathan_friedberg@urmc.rochester.edu*
Frustaci, Anna Maria: *annamaria.frustaci@ospedaleniguarda.it*
Hartmann, Sylvia: *sylvia.hartmann@uk-essen.de*
Herrera, Alex: *aherrera@coh.org*
Hertzberg, Mark: *mhertzberg10@gmail.com*
Hoppe, Richard: *Richard.Hoppe@stanford.edu*
Hutchings, Martin: *martin.hutchings@gmail.com*
Kersten, Marie José: *m.j.kersten@amsterdamumc.nl*
Klapper, Wolfram: *wklapper@path.uni-kiel.de*
Kobe, Carsten: *carsten.kobe@uk-koeln.de*

Küppers, Ralf: *ralf.kueppers@uk-essen.de*
Leppä, Sirpa: *sirpa.leppa@helsinki.fi*
Lewis, David: *david.lewis17@nhs.net*
Mahuad, Carolina: *cmahuad@hospitalaleman.com*
Mauz-Körholz, Christine: *christine.mauz-koerholz@paediat.med.uni-giessen.de*
Moskowitz, Alison: *moskowitz@mskcc.org*
Moskowitz, Craig: *CHM78@miami.edu*
Nijdam, Annelies: *a.nijdam@nki.nl*
Partridge, Linda: *linda.partridge@ucl.ac.uk*
Plattel, Wouter: *w.j.plattel@umcg.nl*
Radford, John: *John.Radford@manchester.ac.uk*
Rossi, Davide: *davide.rossi@ior.usi.ch*
Rusconi, Chiara: *Chiara.Rusconi@istitutotorino.mi.it*
Rutherford, Sarah: *sar2014@med.cornell.edu*
Shipp, Margaret: *Margaret_shipp@dfci.harvard.edu*
Song, Yuqin: *songyuqin622@163.com*
Specht, Lena: *specht@rh.dk*
Steidl, Christian: *CSteidl@bccancer.bc.ca*
Sureda, Anna: *asureda@iconcologia.net*
Thieblemont, Catherine: *catherine.thieblemont@aphp.fr*
van Leeuwen, Flora: *f.v.leeuwen@nki.nl*
Vassilakopoulos, Theodoros P.: *tvassilak@med.uoa.gr*
von Tresckow, Bastian: *Bastian.vonTresckow@uk-essen.de*
Yahalom, Joachim: *yahalomj@mskcc.org*
Zijlstra, Jose: *j.zijlstra@amsterdamumc.nl*
Zinzani, Pier Luigi: *piertuigi.zinzani@unibo.it*



POSTER AWARDS

Bradford S. Hoppe | P102

Ilja Kalashnikov | P043

Reena Pabari | P092

Maria Cristina Piroso | P039

Sophie Teesink | P133

KARL MUSSHOF PRIZE

Best Clinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.

This year's prize for "Best Clinical Abstract" will be awarded for presentation T001 to:

JONATHAN FRIEDBERG

KARL MUSSHOF PRIZE


Best Preclinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.


This year's prize for "Best Preclinical Abstract" will be awarded for presentation T028 to:

CHRISTIAN STEIDL


GÜRZENICH CONGRESS CENTER



First Floor



Ground Floor



Basement

First Floor

Großer Saal	Sat. 26.10.2024	Educational, Scientific Program, Scientific Symposia, Opening Ceremony
	Sun. - Mon. 27.-28.10.2024	Scientific Program, Scientific Symposia
Isabellensaal	Sat. (noon) - Mon. 26.-28.10.2024	Exhibition Hall, Coffee Bar

Ground Floor

Foyer	Sat.-Mon. 26.-28.10.2024	Registration, Internet, Speakers Ready Room
Kleiner Saal and Foyer	Sat. 26.10.2024	Poster Presentation, Welcome Reception
Marsiliussaal	Sat. 26.10.2024	Workshop

 **WC: First Floor, Basement**

 **Wardrobe: Basement**



ISHL13 APP

Scan QR-Code or visit app.ishl.eu
Further information is available at
www.hodgkinsymposium.org